Perimed AB, a leading medical device company in the vascular segment, is thrilled to announce a significant milestone in its growth journey. Serendipity Partners, a leading Nordic healthcare growth investor, has acquired a substantial 49% ownership stake in Perimed AB signifying a strategic partnership that will ensure continued expansion of the company and its products.
This strategic investment comes at a pivotal moment for Perimed which has already established
itself as a global leader in the assessment of macro- and microcirculation. Serendipity Partner's
decision to take a substantial ownership position is a resounding vote of confidence in Perimed's
vision, business model, and team.
"We are delighted to welcome Serendipity Partners as a key stakeholder in our journey," says Björn
Bakken, current owner of Perimed. "This investment not only validates the hard work and
dedication of our team but also positions us for accelerated growth and success in the rapidly growing
market for diagnostic instruments for Diabetic Foot Syndrome and other severe peripheral vascular
conditions. Serendipity Partners brings great experience, industry knowledge, and a shared vision that
aligns seamlessly with our strategic objectives."
The infusion of capital from Serendipity Partners will be instrumental for Perimed’s expansion
plans, with the US as its primary market. The collaboration is expected to unlock synergies that
will enhance operational efficiency and ultimately deliver great value to Serendipity Partners
investors. Partners Lars Mariero, MD PhD and Synne H. Røine, MSc will become members of the
Perimed Board of Directors.
"Perimed has demonstrated exceptional potential, and I am confident that our collaboration will yield
mutually beneficial results. I am excited to contribute to the company's continued success and be part
of its journey to redefine standards in vascular care, says Partner Synne Røine"